middle.news
Why Percheron’s New Cancer Drug License Could Change Its Fortunes
10:33am on Thursday 26th of June, 2025 AEST
•
Biotechnology
Read Story
Why Percheron’s New Cancer Drug License Could Change Its Fortunes
10:33am on Thursday 26th of June, 2025 AEST
Key Points
Exclusive worldwide license for HMBD-002 from Hummingbird Bioscience
Upfront payment of US$3 million plus up to US$287 million in milestones and royalties
HMBD-002 targets VISTA, a novel immune checkpoint in cancer therapy
Completed phase I trial demonstrating safety and pharmacological activity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE